Skip to main content

stock

GLMD · Galmed Pharmaceuticals Ltd.

What Galmed Pharmaceuticals Ltd. reports to the SEC, read from its filings.

Open in the app

Price

The live GLMD price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on GLMD.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
6,581,390 as of 2025-12-31 (XBRL frame CY2025Q4I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
—
Net
—

Returns

ROE
-89.0%
ROA
-62.0%

Health

Current ratio
4.2x
Debt/equity
—

Deep value

NCAV
—
NCAV per share
—
Price/NCAV
Locked
NNWC
—
NNWC per share
—
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30——Gross profit: unreported by this company.—-$2.72M
6-K filed 2026-09-02
2026-03-31——Gross profit: unreported by this company.—-$1.91M
6-K filed 2026-09-02
2025-12-31——Gross profit: unreported by this company.—-$4.82M
20-F filed 2026-03-31
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2025-09-30——Gross profit: unreported by this company.—-$1.89M
6-K filed 2025-11-26
2025-06-30——Gross profit: unreported by this company.—-$2.50M
6-K filed 2026-09-02
2025-03-31——Gross profit: unreported by this company.—-$1.10M
6-K filed 2026-09-02
2024-12-31——Gross profit: unreported by this company.—-$3.21M
20-F filed 2026-03-31
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2024-09-30——Gross profit: unreported by this company.—-$1.91M
6-K filed 2025-11-26
Assets
$18.28M
Equity
$12.74M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31——-$10.31M—
2024-12-31——-$7.52M—
2023-12-31——-$6.91M—
2022-12-31——-$17.87M-$18.50M
2021-12-31——-$32.47M-$32.90M
2020-12-31$0-$30.21M-$28.77M-$26.33M
2019-12-31$0-$22.38M-$20.46M-$14.95M
2018-12-31$2.04M-$10.71M-$9.86M-$9.11M
2017-12-31$1.08M-$12.36M-$12.30M-$12.08M
2016-12-31$467,000—-$16.95M-$12.15M

Company filings

2 offering filings in 12 months

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

No insider buys or sales filed in the last 90 days.

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

None of the tracked funds held this at their last 13F.

News

Stories that named GLMD, and the market events around them.

Sign in to see this

Board

Recent signals

Signals open up here once a member has posted about GLMD.

Signals are informational.

Posts · 0

No posts yet.

Be the first to say something about GLMD.

nakagai

Signals on GLMD come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the GLMD board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Galmed Pharmaceuticals Ltd. (GLMD): SEC filings, financials and insider trades · Nakagai